Key result
Pericarditis and myocarditis are inflammatory diseases with a proposed bimodal pathogenesis, for which immunosuppressive therapy is currently being tested in clinical trials.
Provides a general overview of the pathogenesis and standard management of pericarditis and myocarditis.
Answers are grounded in this paper and cite their sources.
May support trial enrollment in pericarditis and myocarditis; leaves open optimal immunosuppression strategies in practice.
Pericarditis and myocarditis are inflammatory diseases that are often initiated by common viruses. Pericarditis rarely causes serious long-term disability, whereas myocarditis may lead to chronic congestive cardiomyopathy and permanent disability. The pathogenesis of both is proposed to be bimodal, with an early stage characterized by viral replication and a later stage by infiltration of lymphocytes and necrosis of cells secondary to an autoimmune process. Treatment of pericarditis is usually symptomatic. Myocarditis requires bed rest and conventional therapy for congestive heart failure. Efficacy of immunosuppressive therapy for myocarditis is currently being tested in an international multi-center clinical trial.
No takes yet. Share an insight, caveat, or question.
Jan L. Houghton (1992) conducted a review in Pericarditis and myocarditis. Pericarditis and myocarditis are inflammatory diseases with a proposed bimodal pathogenesis, for which immunosuppressive therapy is currently being tested in clinical trials.
Synapse has enriched 10 related papers. Consider them for comparative context: